Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene therapy safety check: 400 cancer patients monitored for years

NCT ID NCT06885424

Knowledge-focused Sponsor: A2 Biotherapeutics Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for delayed side effects and see how long any benefits last. The goal is to better understand the safety and durability of this gene therapy approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Mar 2040

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants previously treated on a A2 Bio GT study

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study 2. Able to provide written informed consent for this long-term follow-up study 3. Able to comply with study requirements Exclusion Criteria: 1\. There are no specific exclusion criteria for this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer colorectal carcinoma colorectal neoplasm head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma kidney cancer malignant pancreatic neoplasm mesothelioma neoplasm non-small cell lung carcinoma ovarian cancer ovarian carcinoma pancreatic neoplasm renal cell carcinoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal carcinoma Colorectal carcinoma (CRC) Head and neck (HNSCC) Head and neck cancer Mesothelioma Non-small cell lung cancer NSCLC Ovarian cancer Ovarian carcinoma Pancreatic cancer Renal cell carcinoma (kidney cancer) Small cell lung cancer ( SCLC ) Solid tumor cancer Solid tumor, unspecified, adult Triple negative breast cancer (TNBC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Banner Health

    Gilbert, Arizona, 85234, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • NYU Langone Medical Center

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.